• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人乳头瘤病毒阴性口腔鳞状细胞癌中的肿瘤微环境、HLA I类分子与抗原加工呈递分子表达

Tumor Microenvironment, HLA Class I and APM Expression in HPV-Negative Oral Squamous Cell Carcinoma.

作者信息

Wickenhauser Claudia, Bethmann Daniel, Kappler Matthias, Eckert Alexander Walter, Steven André, Bukur Jürgen, Fox Bernard Aloysius, Beer Jana, Seliger Barbara

机构信息

Institute of Pathology, University Hospital Halle (Saale), 06112 Halle (Saale), Germany.

Department of Oral, Maxillofacial and Plastic Surgery, University Hospital Halle (Saale), 06120 Halle (Saale), Germany.

出版信息

Cancers (Basel). 2021 Feb 4;13(4):620. doi: 10.3390/cancers13040620.

DOI:10.3390/cancers13040620
PMID:33557271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7914856/
Abstract

Progression of oral squamous cell carcinoma (OSCC) has been associated with an escape of tumor cells from the host immune surveillance due to an increased knowledge of its underlying molecular mechanisms and its modulation by the tumor microenvironment and immune cell repertoire. In this study, the expression of HLA class I (HLA-I) antigens and of components of the antigen processing machinery (APM) was analyzed in 160 pathologically classified human papilloma virus (HPV)-negative OSCC lesions and correlated to the intra-tumoral immune cell response, IFN-γ signaling and to the patient's outcome. A heterogeneous but predominantly lower constitutive protein expression of HLA-I APM components was found in OSCC sections when compared to non-neoplastic cells. Tumoral HLA-I APM component expression was further categorized into the three major phenotypes HLA-I/APM, HLA-I/APM and HLA-I/APM. In the HLA-I/APM group, the highest frequency of intra-tumoral CD8 T cells and lowest number of CD8 T cells close to FoxP3 cells were found. Patients within this group presented the most unfavorable survival, which was significantly evident in stage T2 tumors. Despite a correlation with the number of intra-tumoral CD8 T cells, tumoral JAK1 expression as a surrogate marker for IFN-γ signaling was not associated with HLA-I/APM expression. Thus, the presented findings strongly indicate the presence of additional factors involved in the immunomodulatory process of HPV-negative OSCC with a possible tumor-burden-dependent complex network of immune escape mechanisms beyond HLA-I/APM components and T cell infiltration in this tumor entity.

摘要

口腔鳞状细胞癌(OSCC)的进展与肿瘤细胞逃避宿主免疫监视有关,这是由于对其潜在分子机制以及肿瘤微环境和免疫细胞库对其调节的认识不断增加。在本研究中,分析了160例经病理分类的人乳头瘤病毒(HPV)阴性OSCC病变中HLA I类(HLA-I)抗原和抗原加工机制(APM)成分的表达,并将其与肿瘤内免疫细胞反应、IFN-γ信号传导以及患者预后相关联。与非肿瘤细胞相比,在OSCC切片中发现HLA-I APM成分的组成性蛋白表达存在异质性但主要较低。肿瘤HLA-I APM成分表达进一步分为三种主要表型HLA-I/APM、HLA-I/APM和HLA-I/APM。在HLA-I/APM组中,肿瘤内CD8 T细胞频率最高,靠近FoxP3细胞的CD8 T细胞数量最少。该组患者的生存率最不理想,在T2期肿瘤中尤为明显。尽管与肿瘤内CD8 T细胞数量相关,但作为IFN-γ信号替代标志物的肿瘤JAK1表达与HLA-I/APM表达无关。因此,本研究结果强烈表明,在HPV阴性OSCC的免疫调节过程中存在其他因素,在该肿瘤实体中,可能存在一个超出HLA-I/APM成分和T细胞浸润的、与肿瘤负荷相关的复杂免疫逃逸机制网络。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33fd/7914856/c304cf58667c/cancers-13-00620-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33fd/7914856/c8bcdbeca043/cancers-13-00620-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33fd/7914856/d32f4b125d9b/cancers-13-00620-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33fd/7914856/c304cf58667c/cancers-13-00620-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33fd/7914856/c8bcdbeca043/cancers-13-00620-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33fd/7914856/d32f4b125d9b/cancers-13-00620-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33fd/7914856/c304cf58667c/cancers-13-00620-g003.jpg

相似文献

1
Tumor Microenvironment, HLA Class I and APM Expression in HPV-Negative Oral Squamous Cell Carcinoma.人乳头瘤病毒阴性口腔鳞状细胞癌中的肿瘤微环境、HLA I类分子与抗原加工呈递分子表达
Cancers (Basel). 2021 Feb 4;13(4):620. doi: 10.3390/cancers13040620.
2
Down-regulation of HLA class I antigen-processing machinery components in esophageal squamous cell carcinomas: association with disease progression.食管鳞状细胞癌中HLA I类抗原加工机制成分的下调:与疾病进展的关联
Scand J Gastroenterol. 2009;44(8):960-9. doi: 10.1080/00365520902998679.
3
HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker.原发性喉鳞状细胞癌病变中HLA I类抗原下调作为不良预后标志物
Cancer Res. 2006 Sep 15;66(18):9281-9. doi: 10.1158/0008-5472.CAN-06-0488.
4
Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer.HLA I 类抗原异常与前列腺癌疾病进展和早期复发的相关性研究。
Cancer Immunol Immunother. 2010 Apr;59(4):529-40. doi: 10.1007/s00262-009-0769-5. Epub 2009 Oct 7.
5
Association of defective HLA-I expression with antigen processing machinery and their association with clinicopathological characteristics in Kazak patients with esophageal cancer.HLA-I 表达缺陷与抗原加工机制的关联及其与哈萨克族食管癌患者临床病理特征的关系。
Chin Med J (Engl). 2011 Feb;124(3):341-6.
6
Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma.人宫颈癌中MHC I类抗原加工机制成分的表达缺陷
Int J Oncol. 2001 Dec;19(6):1211-20. doi: 10.3892/ijo.19.6.1211.
7
Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome.头颈部鳞状细胞癌中人类白细胞抗原I类抗原加工机制的缺陷:与临床结局的关联
Clin Cancer Res. 2005 Apr 1;11(7):2552-60. doi: 10.1158/1078-0432.CCR-04-2146.
8
SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells.SHP2 过表达并抑制 pSTAT1 介导的 APM 成分表达、T 细胞趋化因子分泌和头颈癌细胞中的 CTL 识别。
Clin Cancer Res. 2013 Feb 15;19(4):798-808. doi: 10.1158/1078-0432.CCR-12-1517. Epub 2013 Jan 30.
9
Distinct Molecular Mechanisms of Altered HLA Class II Expression in Malignant Melanoma.恶性黑色素瘤中HLA II类分子表达改变的独特分子机制
Cancers (Basel). 2021 Aug 3;13(15):3907. doi: 10.3390/cancers13153907.
10
HLA Class I Antigen Processing Machinery Defects in Cancer Cells-Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease.癌细胞中HLA I类抗原加工机制缺陷——频率、功能意义及临床相关性,特别强调其在恶性疾病基于T细胞免疫治疗中的作用
Methods Mol Biol. 2020;2055:325-350. doi: 10.1007/978-1-4939-9773-2_15.

引用本文的文献

1
Novel vaccination strategies based on optimal stimulation of CD4 T helper cells for the treatment of oral squamous cell carcinoma.基于优化 CD4 T 辅助细胞刺激的新型疫苗接种策略治疗口腔鳞状细胞癌。
Front Immunol. 2024 Jul 5;15:1387835. doi: 10.3389/fimmu.2024.1387835. eCollection 2024.
2
Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML.骨髓肿瘤微环境、MDS 和 CMML 进展为 sAML 中的 HLA-I 和 HLA-Ib 表达对预后的影响。
Oncoimmunology. 2024 Mar 6;13(1):2323212. doi: 10.1080/2162402X.2024.2323212. eCollection 2024.
3
Prognostic and Clinical Significance of Human Leukocyte Antigen Class I Expression in Breast Cancer: A Meta-Analysis.

本文引用的文献

1
The 5-Ws of immunotherapy in head and neck cancer.头颈部肿瘤免疫治疗的“5W”
Crit Rev Oncol Hematol. 2020 Sep;153:103041. doi: 10.1016/j.critrevonc.2020.103041. Epub 2020 Jun 30.
2
A signature of hypoxia-related factors reveals functional dysregulation and robustly predicts clinical outcomes in stage I/II colorectal cancer patients.缺氧相关因子的特征揭示了功能失调,并能有力预测I/II期结直肠癌患者的临床结局。
Cancer Cell Int. 2019 Sep 23;19:243. doi: 10.1186/s12935-019-0964-1. eCollection 2019.
3
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
乳腺癌中人类白细胞抗原 I 类表达的预后和临床意义:一项荟萃分析。
Mol Diagn Ther. 2023 Sep;27(5):573-582. doi: 10.1007/s40291-023-00664-z. Epub 2023 Jul 18.
4
Targeting oral tumor microenvironment for effective therapy.靶向口腔肿瘤微环境以实现有效治疗。
Cancer Cell Int. 2023 May 23;23(1):101. doi: 10.1186/s12935-023-02943-5.
5
Global research trends in immunotherapy for head and neck neoplasms: A scientometric study.头颈部肿瘤免疫治疗的全球研究趋势:一项科学计量学研究。
Heliyon. 2023 Apr 13;9(4):e15309. doi: 10.1016/j.heliyon.2023.e15309. eCollection 2023 Apr.
6
Immune Microenvironment and Immunotherapeutic Management in Virus-Associated Digestive System Tumors.病毒相关性消化系统肿瘤的免疫微环境与免疫治疗管理。
Int J Mol Sci. 2022 Nov 6;23(21):13612. doi: 10.3390/ijms232113612.
7
The impact of tumor immunogenicity on cancer pain phenotype using syngeneic oral cancer mouse models.使用同基因口腔癌小鼠模型研究肿瘤免疫原性对癌症疼痛表型的影响。
Front Pain Res (Lausanne). 2022 Sep 12;3:991725. doi: 10.3389/fpain.2022.991725. eCollection 2022.
8
An Immune-Related lncRNA Signature to Predict the Biochemical Recurrence and Immune Landscape in Prostate Cancer.一种预测前列腺癌生化复发和免疫格局的免疫相关长链非编码RNA特征
Int J Gen Med. 2021 Nov 30;14:9031-9049. doi: 10.2147/IJGM.S336757. eCollection 2021.
9
24th "Nantes Actualités en Transplantation" and 4th "LabEx Immunotherapy-Graft-Oncology" NAT and IGO Joint Meeting "New Horizons in Immunotherapy".第 24 届"南特移植进展"和第 4 届"免疫治疗-移植肿瘤学实验室"联合会议"免疫治疗的新视野"。
Front Immunol. 2021 Sep 3;12:738312. doi: 10.3389/fimmu.2021.738312. eCollection 2021.
10
Distinct Molecular Mechanisms of Altered HLA Class II Expression in Malignant Melanoma.恶性黑色素瘤中HLA II类分子表达改变的独特分子机制
Cancers (Basel). 2021 Aug 3;13(15):3907. doi: 10.3390/cancers13153907.
癌症免疫治疗学会关于免疫治疗头颈部鳞状细胞癌(HNSCC)的共识声明。
J Immunother Cancer. 2019 Jul 15;7(1):184. doi: 10.1186/s40425-019-0662-5.
4
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.CheckMate 141 随机 3 期临床试验的亚组分析:纳武利尤单抗治疗复发或转移性头颈部鳞状细胞癌,超出 RECIST 定义的进展
Cancer. 2019 Sep 15;125(18):3208-3218. doi: 10.1002/cncr.32190. Epub 2019 Jun 27.
5
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.纳武利尤单抗治疗复发或转移性头颈部鳞状细胞癌患者:CheckMate 141 研究中既往接受西妥昔单抗治疗患者的疗效和安全性。
Clin Cancer Res. 2019 Sep 1;25(17):5221-5230. doi: 10.1158/1078-0432.CCR-18-3944. Epub 2019 Jun 25.
6
Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.头颈癌的免疫逃逸:联合治疗的基础
Trends Cancer. 2019 Apr;5(4):208-232. doi: 10.1016/j.trecan.2019.02.007. Epub 2019 Mar 20.
7
Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy.肿瘤微环境中的免疫抑制回路及其对癌症治疗效果的影响。
Virchows Arch. 2019 Apr;474(4):407-420. doi: 10.1007/s00428-018-2477-z. Epub 2018 Oct 29.
8
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA.获得性癌症对联合免疫疗法的耐药性来自 I 类 HLA 的转录丢失。
Nat Commun. 2018 Sep 24;9(1):3868. doi: 10.1038/s41467-018-06300-3.
9
Human Papilloma Virus Specific Immunogenicity and Dysfunction of CD8 T Cells in Head and Neck Cancer.人乳头瘤病毒特异性免疫原性与头颈部癌症中 CD8 T 细胞功能障碍。
Cancer Res. 2018 Nov 1;78(21):6159-6170. doi: 10.1158/0008-5472.CAN-18-0163. Epub 2018 Aug 28.
10
Acquired resistance to cancer immunotherapy.获得性癌症免疫疗法耐药性。
Semin Immunopathol. 2019 Jan;41(1):31-40. doi: 10.1007/s00281-018-0692-y. Epub 2018 Jul 2.